Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Incyte Corp (INCY)
Incyte Corp (INCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,257,614
  • Shares Outstanding, K 224,088
  • Annual Sales, $ 3,395 M
  • Annual Income, $ 340,660 K
  • 60-Month Beta 0.70
  • Price/Sales 3.64
  • Price/Cash Flow 22.76
  • Price/Book 2.52
Trade INCY with:

Options Overview Details

View History
  • Implied Volatility 30.23% ( -0.35%)
  • Historical Volatility 24.41%
  • IV Percentile 79%
  • IV Rank 55.28%
  • IV High 41.15% on 03/24/23
  • IV Low 16.74% on 05/18/23
  • Put/Call Vol Ratio 1.37
  • Today's Volume 128
  • Volume Avg (30-Day) 788
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 21,880
  • Open Int (30-Day) 19,850

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate 1.04
  • Number of Estimates 8
  • High Estimate 1.16
  • Low Estimate 0.92
  • Prior Year 0.44
  • Growth Rate Est. (year over year) +136.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
51.47 +6.29%
on 11/10/23
55.94 -2.22%
on 12/04/23
+0.64 (+1.18%)
since 11/08/23
3-Month
50.27 +8.81%
on 10/31/23
64.84 -15.64%
on 09/11/23
-9.28 (-14.50%)
since 09/08/23
52-Week
50.27 +8.81%
on 10/31/23
86.29 -36.61%
on 01/26/23
-29.41 (-34.97%)
since 12/08/22

Most Recent Stories

More News
3 Biotech Stocks Bursting With Investment Potential

The biotech industry is well-positioned for robust growth thanks to the increasing demand for effective treatments for chronic diseases and the need to serve an aging population. To capitalize on the favorable...

GMAB : 32.28 (-0.25%)
INCY : 54.70 (-0.87%)
ORGO : 3.33 (+18.51%)
Is Roivant Sciences (ROIV) the Right Biotech Stock for Your Portfolio?

While Roivant Sciences (ROIV) has been seeing stable revenue growth, its bottom line is in the red. So, will it be worth owning ROIV now? Let’s discuss some of its key financial metrics to gauge its...

INCY : 54.70 (-0.87%)
OTSKY : 19.3500 (-1.93%)
ROIV : 9.83 (+0.82%)
VRTX : 350.15 (-1.07%)
Incyte: Q3 Earnings Snapshot

Incyte: Q3 Earnings Snapshot

INCY : 54.70 (-0.87%)
The Fight Against Pancreatic Cancer Just Gained a New Ally with $200M VC Firm

VANCOUVER – USA News Group – A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding from prominent individuals and institutions such as MIT, Memorial...

AAPL : 195.71 (+0.74%)
NYT : 46.68 (-1.35%)
ONCY : 1.4000 (unch)
ONC.TO : 1.90 (-0.52%)
MACK : 13.03 (+0.77%)
INCY : 54.70 (-0.87%)
MRTX : 56.49 (-0.35%)
BNTX : 103.43 (+1.48%)
3 Revolutionary Biotech Stocks Worth Investing In

The biotech industry's upward momentum is underpinned by the growth of personalized medicine, orphan drugs, innovative biotech tools, and robust government backing. Hence, revolutionary biotech stocks...

EQ : 0.6800 (+15.25%)
INCY : 54.70 (-0.87%)
PLX : 1.6300 (-4.12%)
REPL : 7.29 (-4.08%)
SNDX : 16.65 (-0.89%)
Exploring the Upside Potential of 3 Biotech Stocks

Given the breakthrough developments, government support, and rising need to treat chronic diseases, the biotech industry is well-positioned to grow steadily. So, it could be wise to invest in quality biotech...

ALKS : 25.86 (-1.15%)
AMGN : 269.12 (-0.81%)
INCY : 54.70 (-0.87%)
Investors Keeping a Close Eye on These 3 Biotech Stocks

Growing adoption of AI technologies by biopharmaceutical companies and growing foothold of personalized medicine are expected to drive growth in the biotech market. Therefore, it could be wise to buy fundamentally...

CORT : 26.54 (-0.71%)
INCY : 54.70 (-0.87%)
REGN : 840.14 (-1.06%)
Argenx's 28% Surge & Promising Product Propel Investor Confidence

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

ARGX : 453.48 (-0.94%)
ABBV : 149.28 (+0.89%)
ABCL : 4.87 (+0.62%)
ALNY : 170.04 (-4.07%)
AMGN : 269.12 (-0.81%)
ANAB : 16.36 (-0.37%)
AZN : 63.25 (-0.41%)
BMY : 50.31 (+0.30%)
INCY : 54.70 (-0.87%)
REGN : 840.14 (-1.06%)
VIE : 53.01 (unch)
Pancreatic Cancer Battle Boosted by $200M VC Firm

/PRNewswire/ -- USA News Group - A new cancer-focused venture capital firm is making headlines, having debuted with $200 million in funding from prominent...

ONC.TO : 1.90 (-0.52%)
ONCY : 1.4000 (unch)
MACK : 13.03 (+0.77%)
INCY : 54.70 (-0.87%)
MRTX : 56.49 (-0.35%)
BNTX : 103.43 (+1.48%)
Pancreatic Cancer Battle Boosted by $200M VC Firm

EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:MACK),(NASDAQ:INCY),(NASDAQ:MRTX),(NASDAQ:BNTX) EQNX::TICKER_END

AAPL : 195.71 (+0.74%)
ONCY : 1.4000 (unch)
ONC.TO : 1.90 (-0.52%)
MACK : 13.03 (+0.77%)
INCY : 54.70 (-0.87%)
MRTX : 56.49 (-0.35%)
BNTX : 103.43 (+1.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2...

See More

Key Turning Points

3rd Resistance Point 56.02
2nd Resistance Point 55.59
1st Resistance Point 55.15
Last Price 54.70
1st Support Level 54.28
2nd Support Level 53.85
3rd Support Level 53.41

See More

52-Week High 86.29
Fibonacci 61.8% 72.53
Fibonacci 50% 68.28
Fibonacci 38.2% 64.03
Last Price 54.70
52-Week Low 50.27

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar